Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daniel Burgess Insider Profile
4 Followers
Daniel Burgess, Director at Cidara Therapeutics, holds 53.50K shares in Nabriva (Ticker: NBRV), holds 3.00K shares in Cidara Therapeutics (Ticker: CDTX), holds ― shares in Arbutus Biopharma (Ticker: ABUS).
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-6.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Daniel Burgess holds in companies
Most Profitable Insider Trade
The most profitable trade made by Daniel Burgess
Daniel Burgess's Trading History
Cidara Therapeutics
Apr 21, 2015
Director
Informative Buy
48.00K
$6.99K
Nabriva
Jul 31, 2020
Director
Uninformative Buy
―
$23.17K
Arbutus Biopharma
―
Director
―
―
Santarus
―
―
―
―
List of latest transactions for each holding click on a transaction to see Daniel Burgess's performance on stock
You May Also Like
Daniel Burgess insider profile FAQ
What is the percentage of profitable transactions made by Daniel Burgess?
The percentage of profitable transactions made by Daniel Burgess is 0%.
What is the average return per transaction made by Daniel Burgess?
The average return per transaction made by Daniel Burgess is -6.60%.
What stocks does Daniel Burgess hold?
Daniel Burgess holds: CDTX, NBRV, ABUS, SNTS stocks.
What was Daniel Burgess’s latest transaction?
Daniel Burgess latest transaction was an Uninformative Buy of ―.
What was Daniel Burgess's most profitable transaction?
Daniel Burgess’s most profitable transaction was an Informative Buy of CDTX stock on April 21, 2015. The return on the trade was -4.90%.
What is Daniel Burgess's role in Cidara Therapeutics?
Daniel Burgess's role in Cidara Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.